Join our daily newsletter At The Bell to receive exclusive market insights
- Aussie pharmaceutical tech Starpharma (SPL) has launched its flagship women’s health product in Asia
- The company has rebranded its VivaGel BV cream to BETADINE BV Gel for the over-the-counter Asian market
- The move is set to provide Starpharma with exposure to over 1.5 billion women across the continent’s healthcare industry
- Asia has become the third global region to receive the product, which is a non-antibiotic topical treatment for bacterial vaginosis (BV)
- Mundipharma has been selected as Starpharma’s Asian distribution partner
- Shares in Starpharma have spike 2.43 per cent today, trading for $1.16 each
Aussie pharmaceutical tech Starpharma (SPL) has launched its flagship women’s health product in Asia.
The company has rebranded its VivaGel BV cream to BETADINE BV Gel for the Asian market. The move is set to provide Starpharma with exposure to over 1.5 billion women across the continent’s healthcare industry.
Asia has become the third global region to receive Vivagel BV, a non-antibiotic topical treatment for bacterial vaginosis (BV).
“We are delighted to achieve another territory launch of VivaGel® BV with Mundipharma,” says Starpharma CEO Dr Jackie Fairly.
“Asia represents an important market for VivaGel® BV and we’re delighted that our breakthrough product will be available to millions of Asian women who suffer from BV,” she explained.
The topical gel will be available over the counter and can be used to both treat and prevent bacterial vaginosis. According to Starpharma, BV is the most common vaginal condition worldwide and is twice as common as thrush.
Mundipharma has been selected as Starpharma’s Asian distribution partner and will continue to roll out the gel following its recent launch in South East Asia.
“Mundipharma has a leading position in feminine care in Asia with its successful international brand BETADINE. We look forward to working with Mundipharma on further registrations and launches across the globe,” Jackie reiterated.
Raman Singh, CEO of Mundipharma, said the launch of the BETADINE BV GEL was a significant addition to the BETADINE product portfolio.
“It is already enabling women across Southeast Asia to access affordable and effective treatment for BV over-the-counter as part of our shared ambition with Starpharma to enhance women’s health’s across Asia.”
Shares in Starpharma have spike 2.43 per cent today, trading for $1.16 each at 3:03 pm AEDT.
